Gout

Pharmaceuticals company presents phase 1 results on drug for severe gout

Published in Blood Weekly, November 18th, 2004

Savient Pharmaceuticals, Inc. (SVNT) presented results from its two phase 1 clinical studies of Puricase (PEGylated uricase) in severe gout in three poster presentations at the 68th Annual Scientific Meeting of the American College of Rheumatology in San Antonio, Texas.

The two phase 1 clinical studies were conducted at Duke University Medical Center under lead investigator John S. Sundy, MD. Each study was designed to evaluate the safety, tolerability, and pharmacokinetics of a range of single doses of Puricase in subjects with hyperuricemia associated with severe refractory gout.

At the time of enrollment in the study, the overall quality of life...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry